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Abstract
Background: During a normal cell cycle, the transition from G2 phase to mitotic phase is triggered by the activation of the
cyclin B1-dependent Cdc2 kinase. Here we report our finding that treatment of MCF-7 human breast cancer cells with
nocodazole, a prototypic microtubule inhibitor, results in strong up-regulation of cyclin B1 and Cdc2 levels, and their
increases are required for the development of mitotic prometaphase arrest and characteristic phenotypes.
Methodology/Principal Findings: It was observed that there was a time-dependent early increase in cyclin B1 and Cdc2
protein levels (peaking between 12 and 24 h post treatment), and their levels started to decline after the initial increase. This
early up-regulation of cyclin B1 and Cdc2 closely matched in timing the nocodazole-induced mitotic prometaphase arrest.
Selective knockdown of cyclin B1or Cdc2 each abrogated nocodazole-induced accumulation of prometaphase cells. The
nocodazole-induced prometaphase arrest was also abrogated by pre-treatment of cells with roscovitine, an inhibitor of
cyclin-dependent kinases, or with cycloheximide, a protein synthesis inhibitor that was found to suppress cyclin B1 and
Cdc2 up-regulation. In addition, we found that MAD2 knockdown abrogated nocodazole-induced accumulation of cyclin B1
and Cdc2 proteins, which was accompanied by an attenuation of nocodazole-induced prometaphase arrest.
Conclusions/Significance: These observations demonstrate that the strong early up-regulation of cyclin B1 and Cdc2
contributes critically to the rapid and selective accumulation of prometaphase-arrested cells, a phenomenon associated
with exposure to microtubule inhibitors.
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Introduction
Nocodazole, a prototypic microtubule inhibitor [1,2], has
anticancer activity and is also widely used in cell biology research
as a tool for synchronization of the cell division cycle [3–6].
Mechanistically, this chemical can bind to tubulins and microtu-
bules, thereby suppressing microtubule dynamics [7]. Disruption
of microtubule formation and function in cells treated with
nocodazole [8,9] or other microtubule inhibitors (e.g., vinblastine,
colchicine, and paclitaxel) [9,10–12] results in suppression of cell
cycle progression, with cells usually arrested in the G2/M phase
(based on flow cytometric analysis of cellular DNA content).
During a normal cell cycle, the progression of cells in the G2
phase to M phase is triggered by the activation of the cyclin B1-
dependent Cdc2 kinase [13–15], which is regulated by a series of
phosphorylation-dephosphorylation events and protein-protein
interactions [16–19]. In general, a cell with a suppressed cyclin
B1/Cdc2 activity would tend to be arrested in the G2 phase,
whereas a cell with an elevated cyclin B1/Cdc2 activity would be
favored to enter mitosis [20]. This general principle is supported
by a large body of experimental observations. For instance, earlier
studies showed that treatment of cells with roscovitine, an inhibitor
of the cyclin-dependent kinases (CDKs), or selective knockdown of
cyclin B and Cdc2 expression with siRNAs, each produced cell
cycle arrest predominantly in the G2 phase, with a simultaneous
reduction of cells in the M phase [21]. However, during the
induction of the G2/M phase cell cycle arrest (based on analysis of
cellular DNA content) following treatment of cells with microtu-
bule inhibitors such as nocodazole and paclitaxel, it has been
observed in some earlier studies that there was a marked increase
in cyclin B1 and Cdc2 protein levels [22–24]. When the
morphology of the cells treated with microtubule inhibitors was
analyzed, it was found that most of the G2/M cell population were
actually arrested in mitotic prometaphase, but not in the G2 phase
[25]. The functional role of this puzzling strong increase in cyclin
B1 and Cdc2 protein levels in the development of mitotic
prometaphase arrest in cells treated with microtubule inhibitors
is not understood at present, which was the focus of our present
investigation. Using nocodazole, a prototypic microtubule inhib-
itor, as a tool drug, here we performed a series of experiments
demonstrating that the strong early up-regulation of cyclin B1/
Cdc2 contributes critically to the rapid accumulation of cells
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e24312selectively arrested in the mitotic prometaphase. In addition, we
found that the mitotic arrest deficient 2 (MAD2) protein, an
important spindle checkpoint protein, is involved in mediating
nocodazole-induced up-regulation of cyclin B1 and Cdc2.
Results
Characterization of nocodazole-induced mitotic arrest
Exposure of MCF-7 human breast cancer cells to nocodazole
reduced cell viability (MTT assay) in a concentration- and time-
dependent manner (Figure 1A). Flow cytometry analysis showed
that nocodazole (250 nM) induced characteristic G2/M-pattern
cell cycle arrest, starting as early as at 3 h after drug treatment and
reached plateau at 14 h (79% compared to 27.3% in control cells)
(Figure 1B). Analyses of the nuclear morphology showed that
nocodazole-treated cells exhibited chromosomal condensation and
segregation (Figure 1C), which are characteristic morphological
changes seen in cells blocked in mitotic prometaphase [26]. Based
on counting the number of prometaphase cells (i.e., the mitotic
index), the time-dependent change in nocodazole-induced mitotic
prometaphase arrest (Figure 1D) matched closely the change in
the combined G2/M cell population (Figure 1B). Together, these
data suggest that nocodazole predominantly induces mitotic
prometaphase arrest in MCF-7 human breast cancer cells in a
time- and concentration-dependent manner.
As shown in Figure S1A and S1B, the induction of
prometaphase arrest was also observed in another human breast
cancer cell line (namely, the ER-negative MDA-MB-435s cells)
following in vitro treatment with nocodazole for 12 or 24 h.
Similarly, the induction of prometaphase arrest by nocodazole was
also observed in MCF-10A cells (a non-tumorigenic human
mammary epithelial cell line) (Figure S2B and S2C). It appears
that MCF-10A cells are more sensitive to the induction of cell
death by nocodazole (data not shown), likely due to the faster
proliferation rate of MCF-10A cells compared to MCF-7 cells
(Figure S2A).
In all three human cell lines tested in this study, we found that
the mitotic arrest induced by nocodazole was associated with a
marked up-regulation of cyclin B1 and Cdc2 protein levels
(Figure 1E, Figure S1C, Figure S2D). This finding confirms
earlier observations with other antitubulin agents [20,27]. Using
MCF-7 cells as a representative model, we further conducted
detailed time-course analysis of the levels of these two cell cycle
proteins. Their levels started to increase at 3 h after nocodazole
treatment and reached a peak between 14 and 24 h, but after the
initial 24 h, their levels were markedly decreased in a time-
dependent manner (Figure 1E). It is of note that the time-
dependent increase in cyclin B1 and Cdc2 levels following
nocodazole treatment closely mirrored the time-dependent
induction of prometaphase arrest (compare Figure 1D and
1E). Moreover, the magnitude of the increase in cyclin B1 and
Cdc2 protein levels and the severity of prometaphase arrest
depended on the concentrations of nocodazole used; in general, a
stronger up-regulation of these two proteins and a greater severity
of prometaphase arrest were seen when higher concentrations of
nocodazole were present (data not shown).
Role of cyclin B1 and Cdc2 in the development of mitotic
prometaphase arrest
Accumulation of cyclin B1 and Cdc2 in the nucleus of a cell is
known to trigger the development of chromosomal condensation
and segregation, which are characteristic morphological changes
seen in cells blocked in prometaphase [25]. To probe whether the
early up-regulation of cyclin B1 and Cdc2 protein levels
contributed to the observed nuclear morphological changes in
nocodazole-treated cells, we first examined the subcellular
localization of these two proteins in control and nocodazole-
treated cells using the immunofluorescence staining approach. As
shown in Figure 1F, while the levels of these two proteins were
very low in both cytosol and nuclei of untreated control cells, their
levels were drastically and selectively increased in the nuclear
compartment of nocodazole-treated cells. This observation
suggests that during the induction of mitotic prometaphase arrest
by nocodazole, there is a marked nuclear accumulation of these
two cell cycle-regulatory proteins.
To provide definitive experimental evidence for the involve-
ment of cyclin B1 and Cdc2 up-regulation in nocodazole-induced
prometaphase arrest, we employed the siRNA approach to
selectively knock down the expression of cyclin B1, Cdc2, or
both. As shown in Figure 2A, 2B, twenty-four h after transfection
with cyclin B1-specific siRNA (si-cyclin B1), cells were treated with
nocodazole and then harvested for Western blot analysis of cyclin
B1 and Cdc2 levels. Knockdown of cyclin B1 abrogated
nocodazole-induced increase in both cyclin B1 and Cdc2 proteins
compared with control siRNA-transfected cells. Moreover,
immunofluorescence staining using anti-cyclin B1 antibodies
showed that transfection with si-cyclin B1 diminished nocoda-
zole-induced nuclear accumulation of cyclin B1 protein
(Figure 2C). These changes were accompanied by a reduction
in the degree of chromosomal condensation and segregation, as
well as a decrease in the population of prometaphase cells (from
58.0% to 23.7%, P,0.05) (Figure 2D). Notably, in cells with
cyclin B1 knockdown, treatment with nocodazole caused a smaller
increase in the combined G2/M cell population (assessed by flow
cytometric analysis) (Figure 2E). These data indicate that cyclin
B1 knockdown predominantly decreases the population of
prometaphase cells while it only slightly reduces the combined
G2/M cell population.
Similarly, knockdown of Cdc2 abrogated the nocodazole-
induced accumulation of Cdc2, but the cyclin B1 level was only
modestly reduced in comparison with the control siRNA-
transfected cells (Figure 3A, 3B). Immunofluorescence staining
using anti-Cdc2 antibodies showed that transfection with Cdc2
siRNAs significantly reduced nocodazole-induced nuclear accu-
mulation of Cdc2 protein (Figure 3C). Similar to the observations
with cyclin B1, knockdown of Cdc2 was associated with a
reduction in prometaphase cells (from 58.0% to 24.0%)
(Figure 3D). Collectively, these results suggest that the marked
increase in cyclin B1 and Cdc2 protein levels contributes to the
accumulation of prometaphase-blocked cells following nocodazole
treatment. Following Cdc2 knockdown, the population of G2/M-
arrested cells as assessed by flow cytometry analysis was only
mildly reduced after nocodazole treatment (data not shown).
These data indicate that knockdown of Cdc2, similar to what was
observed with cyclin B1 knockdown, predominantly decreases the
population of prometaphase cells while it affects the combined G2/
M cell population to a much lesser degree.
Role of MAD2 protein in mediating cyclin B1 and Cdc2
up-regulation and prometaphase arrest in nocodazole-
treated cells
MAD2, an important spindle checkpoint protein, can block the
progression through the metaphase-to-anaphase transition by
binding to unattached kinetochores [28]. In addition, during the
development of prometaphase arrest, this protein can also inhibit
the activity of the anaphase promoting complex (APC) by
sequestering Cdc20 until all chromosomes are attached by
microtubules and properly aligned at the metaphase plate. To
Nocodazole-Induced Prometaphase Arrest
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e24312Figure 1. Induction of cell cycle arrest and cyclin B1/Cdc2 activation in MCF-7 cells by nocodazole (Noco). A. Changes in cell viability
(MTT assay) after treatment of cells with 250 nM nocodazole for different lengths of time. Each data point is the mean 6 S.D. from four replicate
measurements from one representative experiment. B. Time-dependent induction of G2/M cell cycle arrest following treatment with nocodazole.
Cells were seeded at 5610
4 cells/mL and then treated with 250 nM nocodazole for 3, 6, 14, 24, 48 and 72 h. Cells were harvested and analyzed using
flow cytometry. C. Cells were treatment with 250 nM nocodazole for 12 or 24 h, stained with Hoechst-33342, and examined in a phase contrast (PC)
microscope (upper panel) or a fluorescence microscopy (lower panel) (at 6200 magnification). As shown, many cells are arrested in mitosis
(prometaphase) after 250 nM treatment. D. Cells were treated with 250 nM nocodazole for 3, 6, 14, 24, 48 and 72 h. The morphology of cells arrested
in prometaphase (based on 200 or more nuclei in each sample) was scored by fluorescence microscopy. Each bar is the mean 6 S.D. value from three
separate experiments. * P,0.05, ** P,0.01 versus vehicle-treated control. E (upper part). Time-dependent changes in cyclin B1 and Cdc2 protein
levels following nocodazole treatment. Cells were treated with nocodazole (250 nM) for the length of time as indicated, and whole cell lysates were
prepared. An equal amount of protein lysates was electrophoretically separated on the 10% SDS-polyacrylamide gel, and transferred to nitrocellulose
membrane. Western blots were detected using specific antibodies against cyclin B1, Cdc2 (CDK1), MAD2, and Cdc20 on an enhanced
chemiluminescence (ECL) apparatus. Membrane was stripped for determining the levels of GAPDH as a loading control. E (lower part). The relative
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Cdc2 up-regulation in nocodazole-treated cells, we first examined
the time-dependent changes of MAD2 protein as well as a
representative target protein, Cdc20, during nocodazole-induced
cell cycle arrest. We found that the MAD2 protein level was only
slightly increased between 6–14 h after nocodazole treatment,
whereas Cdc20 protein level remained unchanged during the first
14 h and was markedly decreased at 24 and 48 h (Figure 1E).
Next, we selectively knocked down MAD2 expression and then
studied its effect on nocodazole-induced changes in cyclin B1/
Cdc2 levels as well as prometaphase arrest. As shown in Figure 4A
and 4B, 24 h after transfection with the MAD2 siRNA (si-
MAD2), cells were treated with nocodazole and then harvested for
Western blotting of cyclin B1, Cdc2, MAD2, and Cdc20 protein
levels. si-MAD2-transfected cells had a markedly reduced MAD2
protein level, suggesting that the knockdown was effective.
Surprisingly, MAD2 knockdown completely abrogated the
nocodazole-induced up-regulation of cyclin B1 and Cdc2
compared with control siRNA-transfected cells (Figure 4A, 4B).
However, the level of Cdc20 was not appreciably altered in
MAD2-knockdown cells treated with nocodazole (Figure 4A,
4B).
Immunofluorescence staining showed that cells with MAD2
knockdown had markedly reduced nuclear accumulation of cyclin
B1 and MAD2 proteins following nocodazole treatment compared
to cells transfected with control siRNA, which had highly elevated
levels of nuclear cyclin B1 and MAD2 (Figure 4C). These
changes were accompanied by a reduction in the degree of
chromosomal condensation and segregation as well as a drastic
decrease in the population of mitotic prometaphase cells from 44%
to 4.2% (P,0.01) at 12 h and 38% to 4.8% (P,0.01) at 24 h
(Figure 4D). Similar to what was observed with cyclin B1 or Cdc2
knockdown, knockdown of MAD2 only weakly affected the total
cellular DNA content (i.e., the combined G2/M cell population) in
nocodazole-treated cells (Figure 4E). These results show that up-
regulation of cyclin B1 and Cdc2 protein levels and the
development of mitotic arrest both depend on the presence of
MAD2 protein. Here it is also of note that MAD2 knockdown
produced a stronger suppression of the prometaphase arrest than
knockdown of cyclin B1 and Cdc2. This reason is because MAD2
knockdown will not only reduce the levels of cyclin B1 and Cdc2
(as shown in Figure 4), which reduces prometaphase arrest in the
same way as does cyclin B1/Cdc2 knockdown, but it will also
allow prometaphase cells to proceed through metaphase and then
enter anaphase, which is an inherent function of MAD2.
Pharmacological inhibition of Cdc2 abrogates
nocodazole-induced prometaphase arrest
The series of experiments as described above suggested that up-
regulation of cyclin B1/Cdc2 plays a critical role in the
development of the characteristic prometaphase arrest seen in
cells treated with microtubule inhibitors. This mechanistic
explanation was put to further test by examining the effects on
cell cycle changes when nocodazole was used in combination with
rescorvitine, which is an inhibitor of the cyclin-dependent kinases
(including Cdc2), or with cycloheximide (CHX), which is a protein
sysnthesis inhibitor. The findings are briefly summarized below.
Effect of roscovitine. To study the modulating effect of
roscovitine, MCF-7 cells were treated with 10, 20 and 30 mM
roscovitine alone or in combination with 250 nM nocodazole for
12 h. Roscovitine (at 20 and 30 mM) markedly reduced
nocodazole-induced increase in cyclin B1 levels (Figure 5A),
and a similar reduction was seen with Cdc2 protein levels (data not
shown).
Flow cytometric analysis of the cellular DNA content showed
that treatment of cells with roscovitine alone increased the
combined G2/M-arrested cells in a concentration-dependent
manner, which is consistent with an earlier study [21]. During
the development of roscovitine-induced G2/M arrest, the
population of prometaphase cells is only slightly increased
compared to cells treated with nocodazole (Figure 5C). Our
observations are in agreement with the earlier study showing that
roscovitine blocks MCF-7 cells in the G2 phase [21]. However,
when roscovitine was used in combination with nocodazole, it
strongly suppressed nocodazole-induced accumulation of the G2/
M cell population (flow cytometric analysis, Figure 5B) as well as
prometaphase-arrested cells (Figure 5C, 5D). The dose-depen-
dent effect of roscovitine in suppressing nocodazole-induced
accumulation of both G2/M and prometaphase cell populations
is closely correlated with its ability to suppress cyclin B1 up-
regulation in nocodazole-treated cells (Figure 5). Together, these
data show that roscovitine, when used in combination with
nocodazole, can inhibit cells from entering prometaphase by
keeping them staying at the end of G2 phase. Mechanistically,
roscovitine exerts this effect through inhibiting Cdc2 activity plus
suppressing nocodazole-induced cyclin B1 up-regulation.
Effect of cycloheximide (CHX). To investigate the
modulating effect of CHX (a protein synthesis inhibitor) on
nocodazole-induced cyclin B1/Cdc2 accumulation and mitotic
arrest, MCF-7 cells were treated nocodazole alone or in
combination with CHX (1 mg/mL) for 12 h. Following the
treatment, cells were divided into 3 groups for Western blotting
analysis of cell cycle regulatory proteins, for flow cytometric
analysis of cell cycle change, and for Hoechst staining of the
nuclear morphological change. As shown in Figure 6A, co-
treatment with CHX strongly suppressed nocodazole-induced
early increase in cyclin B1 and Cdc2 levels. The suppression of
nocodazole-induced early increase in cyclin B1 and Cdc2 protein
levels by CHX was accompanied by a strong reduction in the
population of G2/M-arrested cells (from 79.6 to 20.2%, flow
cytometry analysis) (Figure 6B, upper panel) and abrogation of
the development of prometaphase arrest (Figure 6B, lower
panel; Figure 6C). Notably, treatment of cells with CHX alone
did not appreciably alter the G1 phase cell population (Figure 6B).
These observations further support the conclusion that increased
de novo synthesis of cyclin B1 and Cdc2 contributes importantly to
the development of prometaphase arrest in cells treated with
nocodazole.
Discussion
In a normal cell cycle, the transition from G2 phase to mitotic
phase is triggered by the activation of the cyclin B1/Cdc2
complex. Cells with a suppressed cyclin B1/Cdc2 activity would
be arrested in the G2 phase, whereas cells with an elevated cyclin
protein levels for cyclin B1, Cdc2, MAD2, and Cdc20 were calculated according to their densitometry readings, which were normalized according to
the corresponding readings for the GAPDH protein bands. Each value is mean 6 S.D. from three replicate determinations. * P,0.05, ** P,0.01 versus
vehicle-treated control. F. Cells were treatment with 250 nM nocodazole for 12 h and analyzed using immunofluorescence staining for cyclin B1 and
Cdc2. Representative photographs were taken under a fluorescence microscope (original magnification, 6200).
doi:10.1371/journal.pone.0024312.g001
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PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e24312Figure 2. Effect of cyclin B1 knockdown on the development of nocodazole (Noco)-induced prometaphase arrest in MCF-7 cells.
A. Cells were transfected with cyclin B1 siRNA (si-cyclin B1) and the negative control siRNAs (si-Con), 24 h later, cells were exposed to 250 nM
nocodazole for additional 12 h. Then the whole cell lysates were analyzed for the levels of cyclin B1 and Cdc2by Western immunoblotting. B. Relative
protein levels of cyclin B1 and Cdc2 are calculated according to densitometry readings, which are then normalized according to the corresponding
readings for the GAPDH protein bands. Each value is mean 6 S.D. from three replicate determinations. * P,0.05, ** P,0.01 versus vehicle-treated
control;
# P,0.05,
## P,0.01 versus nocodazole treatment. C. Cells were transfected with si-cyclin B1 or siRNA negative control and then further
treated with nocodazole (250 nM) for 12 h. Cells with cyclin B1 knockdown were analyzed using immunofluorescent staining for cyclin B1.
Representative photographs were taken using a fluorescence microscope (original magnification,6200) or a phase contrast (PC) microscope (6200).
D. Quantitative data on prometaphase-arrested cells. Each bar is a mean 6 S.D. value from three separate experiments. * P,0.05, ** P,0.01 versus
the vehicle-treated control;
# P,0.05 versus nocodazole treatment. E. The DNA content of cells was analyzed using flow cytometry as described in
the Material and Methods section.
doi:10.1371/journal.pone.0024312.g002
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PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e24312Figure 3. Effect of Cdc2 knockdown on the development of nocodazole (Noco)-induced prometaphase arrest in MCF-7 cells. A. Cells
were transfected with siRNA Cdc2 (si-Cdc2) and the negative control siRNAs (si-Con), and 24 h later, cells were exposed to 250 nM nocodazole for
additional 12 h. Then the whole cell lysates were analyzed for Cdc2 and cyclin B1 levels using Western immunoblotting. B. The relative protein levels
of Cdc2 and cyclin B1 are calculated according to their densitometry readings, which are normalized according to the corresponding readings for the
GAPDH protein bands. Each value is mean 6 S.D. from three replicate measurements. * P,0.05 versus vehicle-treated control;
# P,0.05 versus
nocodazole treatment. C. Cells were transfected with si-cyclin B1 or siRNA negative control and then further treated with nocodazole (250 nM) for
12 h. Cells with Cdc2 knockdown were analyzed using immunofluorescent staining. Representative photographs were taken using a fluorescence
microscopy (original magnification,6200) or a phase contrast microscope (6200). D. Quantitative data on prometaphase-arrested cells. Each bar is a
mean 6 S.D. value from three separate experiments. ** P,0.01 versus the vehicle-treated control;
## P,0.01 versus nocodazole treatment.
doi:10.1371/journal.pone.0024312.g003
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through mitosis [15]. The results of our present study confirm the
earlier interesting observation showing that treatment of cancer
cells with microtubule inhibitors such as vinblastine, colchicine
and paclitaxel, causes a strong up-regulation of cyclin B1 and
Cdc2 protein levels [9–12], while the level of Cdc2 phosphory-
Figure 4. Effect of MAD2 knockdown on the development of nocodazole (Noco)-induced prometaphase arrest in MCF-7 cells.
A. Cells were transfected with siRNA MAD2 (si-MAD2) and the negative control siRNAs (si-Con), and 24 h later, cells were exposed to 250 nM
nocodazole for additional 12 h. Then the whole cell lysates were analyzed for Cdc2, cyclin B1, MAD2, and Cdc20 levels using Western
immunoblotting. B. The relative protein levels of Cdc2, cyclin B1, MAD2, and Cdc20 are calculated according to their densitometry readings, which
are normalized according to the corresponding readings for the GAPDH protein bands. Each value is mean 6 S.D. from three replicate measurements.
* P,0.05 versus vehicle-treated control;
# P,0.05 versus nocodazole treatment. C. Cells were transfected with si-MAD2 or siRNA negative control and
then further treated with nocodazole (250 nM) for 12 h. Cells with Cdc2 knockdown were analyzed using immunofluorescent staining.
Representative photographs were taken using a fluorescence microscopy (original magnification, 6200). D. Quantitative data on prometaphase-
arrested cells. Each bar is a mean 6 S.D. value from three separate experiments. ** P,0.01 versus the vehicle-treated control;
# P,0.05 versus
nocodazole treatment. E. The DNA content of cells was analyzed using flow cytometry as described in the Material and Methods section.
doi:10.1371/journal.pone.0024312.g004
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changed [23]. The observed up-regulation of cyclin B1 and Cdc2
is expected to result in increased functionality of the cyclin B1/
Cdc2 complex. However, under these conditions, a higher
percentage of cells are actually found to be selectively arrested in
mitotic prometaphase; by contrast, control cells that are not
treated with nocodazole and have much lower cyclin B1/Cdc2
levels actually have far fewer cells arrested in prometaphase.
Apparently, these seemingly paradoxical changes are caused by
the presence of nocodazole, which would create a false signal in
Figure 5. Effect of rescorvitine (Rosc) on nocodazole (Noco)-induced prometaphase arrest in MCF-7 cells. A (upper panel). Cells were
pre-treated for 2 h with roscovitine (10, 20, and 30 mM) and then stimulated for additional 12 h with 250 nM nocodazole. Total cell lysates were
analyzed by Western immunoblotting for cyclin B1. A (lower panel). The relative protein levels cyclin B1 are calculated according to their
densitometry readings, which are normalized according to the corresponding readings for the GAPDH protein bands. Each value is mean 6 S.D. from
three replicate measurements. ** P,0.01 versus vehicle-treated control;
# P,0.05,
## P,0.01 versus nocodazole treatment. B. Cells were pre-treated
for 2 h with roscovitine (10, 20, and 30 mM) and then stimulated for additional 12 h with 250 nM nocodazole. The DNA content of cells was analyzed
using flow cytometry as described in the Material and Methods section. C. Nuclei were stained with Hoechst-33342, and examined using a
fluorescence microscope for prometaphase cells (original magnification, 6200). D. Quantitative data on prometaphase-arrested cells. Each bar is a
mean 6 S.D. value from three separate experiments. ** P,0.01 versus the vehicle-treated control;
## P,0.01 versus nocodazole treatment.
doi:10.1371/journal.pone.0024312.g005
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B1/Cdc2 activity to proceed through mitosis. Consequently, cells
arrested in prometaphase would increase their cyclin B1 and Cdc2
levels, as a cellular compensatory response to nocodazole
treatment. As discussed below, the results of this study provide a
series of experimental evidence in support of the notion that the
strong, early up-regulation of cyclin B1 and Cdc2 following
nocodazole treatment contributes critically to the development of
prometaphase arrest as well as some of its unique features.
Earlier studies have shown that a rapid, excessive activation of
the cyclin B1-dependent Cdc2 in G2 phase cells can result in
aberrant entry into mitotic phase [29,30]. Moreover, premature
nuclear accumulation of the cyclin B1/Cdc2 complex will trigger
chromosomal condensation and segregation [29,30]. The results of
our present study show that the marked early increase in cyclin B1
and Cdc2 levels is accompanied by rapid nuclear accumulation of
these two proteins, in conjunction with the development of
characteristic nuclear chromosomal condensation and segregation.
In addition, we found that selective knockdown of cyclin B1 and
Cdc2 strongly reduced the severity of nuclear chromosomal
condensation and segregation as well as prometaphase arrest.
Similar reductions in nuclear chromosomal condensation and
segregation as well as prometaphase arrest were observed in
nocodazole-treated cells when these cells were co-treated with
roscovitine (an inhibitor of the cyclin-dependent kinases) or CHX
(a protein synthesis inhibitor that reduces the levels of both cyclin
B and Cdc2 in nocodazole-treated cells). Based on these
experimental observations, it is reasonable to suggest that a
stronger initial compensatory up-regulation of the cyclin B1/Cdc2
level following nocodazole treatment would result in severer
prometaphase arrest because higher cyclin B/Cdc2 levels likely
would bring about a severer degree of nuclear condensation and
Figure 6. Effect of cycloheximide (CHX) on nocodazole-induced prometaphase arrest in MCF-7 cells. A (left panel). Cells were pre-
treated for 2 h with cycloheximide (5 mg/mL) and then stimulated for additional 12 h with 250 nM nocodazole. Total cell lysates were analyzed by
Western immunoblotting for cyclin B1 and Cdc2. A (right panel). The relative protein levels of cyclin B1 and Cdc2 are calculated according to their
densitometry readings, which are normalized according to the corresponding readings for the GAPDH protein bands. Each value is mean 6 S.D. from
triplicate measurements. * P,0.05 versus vehicle-treated control;
# P,0.05 versus nocodazole treatment. B (upper panel). Cells were pre-treated for
2 h with cycloheximiden (5 mg/mL) and then stimulated for additional 12 h with 250 nM nocodazole. The DNA content of cells was analyzed using
flow cytometry as described in the Material and Methods section. B (lower panel). Nuclei were stained with Hoechst-33342, and examined using a
fluorescence microscope for prometaphase cells (original magnification, 6200). C. Quantitative data on prometaphase-arrested cells. Each bar is a
mean 6 S.D. value from three separate experiments. ** P,0.01 versus the vehicle-treated control;
## P,0.01 versus nocodazole treatment.
doi:10.1371/journal.pone.0024312.g006
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observation that higher levels of cyclin B1 and Cdc2 were induced
when higher concentrations of nocodazole were present, which
causes a higher degree of microtubule inhibition and severer
prometaphase arrest.
In this study, we found that knockdown of MAD2 almost
completely abrogated nocodazole-induced up-regulation of cyclin
B1 and Cdc2, suggesting that their up-regulation requires the
presence of MAD2. At present, the mechanism by which
nocodazole causes cyclin B1 and Cdc2 up-regulation is not
understood. It is known that MAD2, acting through direct physical
interaction with Cdc20 [31,32], can inhibit the activity APC, a
ubiquitin-protein ligase that tags proteins (including cyclin B1/
Cdc2) for degradation [33]. We found that when the cells with
MAD2 knockdown are treated with nocodazole, their Cdc20
protein level is essentially not altered while their cyclin B1 and
Cdc2 up-regulation is completely abrogated (Figure 4). These
observations suggest that a reduction in Cdc20-APC function
likely is not the main reason for the observed strong up-regulation
of cyclin B1 and Cdc2 in nocodazole-treated cells. In support of
this suggestion, we also found that treatment of these cells with
CHX almost completely suppresses the up-regulation of cyclin B1
and Cdc2 in nocodazole-treated cells, which clearly suggests that
increased de novo protein synthesis is involved their up-regulation.
Roscovitine is a well-known inhibitor of the cyclin-dependent
kinases. Interestingly, we found that treatment of cells with
roscovitine also strongly suppresses nocodazole-induced up-
regulation of cyclin B1 protein, although the mechanism of this
suppression is not clear. Flow cytometric analysis of the cellular
DNA content showed that the combined G2/M cell population is
increased following treatment with roscovitine alone, but the
population of prometaphase cells is only slightly increased. Our
observations are in agreement with the earlier observation that
roscovitine blocks MCF-7 cells in the G2 phase [21]. However,
when roscovitine was used in combination with nocodazole, it
strongly suppressed nocodazole-induced accumulation of the G2/
M cell population as well as prometaphase cells. The dose-
dependent effect of roscovitine in suppressing nocodazole-induced
accumulation of both G2/M and prometaphase cell populations is
closely correlated with its ability to suppress cyclin B1 up-
regulation in nocodazole-treated cells. These data show that
roscovitine, by inhibiting Cdc2 activity plus suppressing nocoda-
zole-induced cyclin B1 up-regulation, inhibits cells from entering
prometaphase by keeping them in the G2 phase when it is used
together with nocodazole.
Co-treatment of cancer cells with CHX and nocodazole was
also found to completely suppress the development of mitotic
arrest. Since treatment of cells with CHX does appreciably affect
the population of G1 phase cells (Figure 6B), the modulating
effect of CHX on nocodazole-induced prometaphase arrest can be
fully explained on the basis of its strong suppression of nocodazole-
induced up-regulation of cyclin B1 and Cdc2 proteins. It is of note
that the combination treatment of cells with CHX and nocodazole
does not cause a stronger cell death; instead, it appears that these
two agents can antagonize the cytotoxic effect of each other. This
observation offers a mechanistic basis that these two classes of
agents should not be used in combination in anticancer
chemotherapy.
Interestingly, although flow cytometric analysis (based on
measurement of cellular DNA content) shows that cells treated
with nocodazole or roscovitine exhibit a similar G2/M cell cycle
arrest pattern, the true nature of their cell cycle arrest is actually
very different, based on the comparisons made in this study. While
roscovitine predominantly induces G2 phase arrest (with minimal
accumulation of prometaphase cells), nocodazole predominantly
induces prometaphase arrest, along with a reduction in the G2
phase cell population. Similar to what we have observed with
roscovitine, a selective knockdown of cyclin B1 and Cdc2 also
results in a significant decrease in prometaphase cells, while it does
not markedly affect the population of G2 phase cells. Based on the
mechanistic explanations developed in this study, these results are
reasonable because chemical inhibition or down-regulation of
cyclin B1/Cdc2 will only block cells that have already completed
DNA replication in the G2 phase from entering mitosis but they
will not produce significant prometaphase arrest. Our observations
are in agreement with this mechanistic explanation.
Nocodazole has been commonly used as a tool agent in cell
biology to induce synchronization of the cell cycle at the G2/M
phase. Based on the results of our present study, since this agent
would predominantly produce prometaphase arrest (accompanied
by aberrant chromosomal condensation and segregation resulting
from extensive nuclear accumulation of cyclin B1 and Cdc2), this
method of cell cycle synchronization may not be ideal for the
purpose of studying normal cell cycles. In comparison, the use of a
selective inhibitor of cyclin B1 or Cdc2 or the combined use of
both inhibitors would seem to be a better approach given that
these inhibitors will only accumulate G2 phase cells by slowing
down the entry of G2 phase cells into M phase but will not cause
severe prometaphase arrest and subsequent mitotic catastrophe as
seen in cells treated with microtubule inhibitors.
In summary, largely based on the findings made in the present
study, the mechanistic explanation for the critical role of the cyclin
B1 and Cdc2 up-regulation in nocodazole-treated cells in the
development of characteristic prometaphase arrest is schematically
depicted in Figure 7. The presence of nocodazole will cause
disruption of microtubule formation in prometaphase cells, which
subsequently results in failure of the microtubules to attach to
kinetochores on the chromosomes. The unattached kinetochores
Figure 7. Schematic explanation of the contribution of an early
cyclin B1/Cdc2 up-regulation to the development of prometa-
phase arrest in cells treated with nocodazole. Treatmentofcancer
cells with nocodazole causes microtubule disruption and thereby
prevents microtubules from attaching to kinetochores in prometaphase
cells. The unattached kinetochores will be bound by MAD2, which
prevents the progression from prometaphase to metaphase and
anaphase. It is speculated that the kinetochore-bound MAD2 protein
plays an important role in mediating the up-regulation of cyclin B1 and
Cdc2 proteins in prometaphase-arrested cells. Therapid increase of these
two cell cycle proteins in prometaphase cells and particularly their
accumulation in the nuclei are expected to be largely responsible for the
development of characteristic nuclear phenotypes. Following a pro-
longed prometaphase arrest, the nocodazole-treated cells are expected
to undergo cell death via intrinsic apoptosis pathways.
doi:10.1371/journal.pone.0024312.g007
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binding of MAD2 at the kinetochores prevents the progression
from prometaphase to metaphase and further to anaphase. It is
speculated that the prometaphase arrest then creates a feedback
up-regulation of cyclin B1 and Cdc2 protein levels, likely mediated
through the kinetochore-bound MAD2 protein. The rapid rise of
these two cell cycle proteins in prometaphase cells and particularly
their accumulation in the nuclei are expected to be largely
responsible for the development of characteristic nuclear pheno-
types. Following a prolonged prometaphase arrest, the nocoda-
zole-treated cells are expected to undergo cell death via intrinsic
apoptosis pathways.
Materials and Methods
Reagents
Nocodazole, roscovitine, cycloheximide, and Eagle’s minimum
essential medium (EMEM) were obtained from Sigma, and fetal
bovine serum (FBS) from HyClone (South Logan, UT). The
antibiotics solution (containing 10,000 U/mL penicillin and
10 mg/mL streptomycin) was obtained from Invitrogen, and the
trypsin-versene mixture (containing 0.25% trypsin and 0.02%
EDTA) from Lonza Walkersville (Walkersville, MD). Anti-Cdc2
(Cdk1), anti-cyclin B1, and GAPDH antibodies were purchased
from Cell Signaling Technology (Beverly, MA). Nocodazole was
dissolved in 200-proof ethanol and stored at 220uC.
Cell culture and MTT assay
MCF-7 and MDA-MB-435s human breast cancer cells and
MCF-10A human mammary epithelial cells were obtained from
the American Type Culture Collection (ATCC, Manassas,
Virginia). The culture medium for MCF-7 cells was EMEM
supplemented with 10% FBS, 2 mg/mL insulin, 0.5 mM sodium
pyruvate, 10 mM nonessential amino acids, 2 mM L-glutamine,
and antibiotics (100 units/mL penicillin and 100 mg/mL strepto-
mycin). The medium for MDA-MB-435s cells was the Iscove’s
modified MEM containing 10% FBS and 3.024 g/L NaHCO3,
and antibiotics. For culturing MCF-10A cells, a special mammary
epithelium basal medium (MEBM, obtained from Lonza, Walk-
ersville, MD) was used. This medium did not contain serum but
was supplemented with an unspecified amount of epidermal
growth factor, insulin, bovine pituitary extract, and hydrocorti-
sone. These human cells were cultured at 37uC under 5% CO2,
and were sub-cultured every 3 to 4 days. For determining cell
viability, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay was used. MTT (10 mL, at 5 mg/mL) was
added to each well at a final concentration of 500 mg/mL, and the
mixture was further incubated for 1 h at 37uC, and the liquid in
the wells was removed thereafter. DMSO (100 mL) was then
added to each well, and the absorbance was read with a UV Max
microplate reader (Molecular Devices, Palo Alto, CA, USA) at
560 nm. Unless indicated otherwise, the relative cell density
usually was expressed as a percentage of the control group that was
not treated with nocodazole.
Crystal violet staining for estimation of cell number
To estimate the cell number, crystal violet staining was used as
described earlier [34]. MCF-7 and MCF-10A cells were seeded in
96-well plates at a density of 5000 cells/well in cell culture media.
At the end of the culture, the medium was discarded, and cells
were fixed with 100 mL 1% glutaraldehyde at room temperature
for 20 min. Glutaraldehyde was then discarded, and the cells were
stained using 50 mL 0.5% crystal violet at room temperature for
15 min. After the crystal violet solution was discarded and rinsed
three times with water, cells were solubilized in 100 mL 0.5%
Triton X-100, followed by addition of 100 mL 200-proof ethanol.
The UV absorbance at 560 nM was read on a UV max
microplate reader (Molecular Device, Palo Alto, CA), and the
value was used to reflect the relative cell number.
Western blotting
For Western blotting, cells were washed first with phosphate-
buffered saline (PBS) and then suspended in 100 mL lysis buffer
(containing 20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1%
Triton X-100, 10 mL/mL protease inhibitor cocktail, pH 7.5).
The amount of proteins was determined using the BioRad protein
assay (BioRad, Hercules, CA). An equal amount of proteins was
loaded in each lane, separated by 10% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE), and then electrically transferred to a
polyvinylidene difluoride membrane (BioRad). After blocking the
membrane using 5% skim milk, target proteins were immunode-
tected using specific antibodies. Thereafter, the horseradish
peroxidase (HRP)-conjugated anti-rabbit IgG was applied as the
secondary antibody, and the positive bands were detected using
Amersham ECL Plus Western blotting detection reagents (GE
Healthcare, Piscataway, NJ).
Immunofluorescent microscopy
For immunocytochemical analysis, cells were first washed three
times with PBS and fixed in 3% paraformaldehyde solution (3%
paraformaldehyde, 0.1 mM CaCl2 and 0.1 mM MgCl2 in PBS,
pH 7.4) for 10 min. Cells were then washed three times with PBS,
permeabilized in 0.2% TritonH X-100/PBS for 5 min, and
washed again three times with PBS. They were blocked with
10% normal goat serum (Jackson Immuno Research Labs, West
Grove, PA) for 1 h, and washed with PBS. The cyclin B1 protein
was detected using the cyclin B1 polyclonal antibodies (1:100
dilution; Cell Signaling Technology), and Cdc2 protein was
detected using the Cdc2 polyclonal antibodies (1:100 dilution; Cell
Signaling Technology). The first antibodies were incubated for
24 h at 4uC and followed by multiple washes in PBS. The same
procedures were repeated with a fluorescein isothiocyanate
(FITC)-conjugated secondary antibody (1:200, Jackson Immuno
Research Labs). The nuclei were stained with Hoechst-33342, and
the coverslips were mounted on slides with Vectashield Mounting
Medium (Vector Laboratories, Burlingame, CA). Fluorescein
images were captured using a confocal fluorescence microscope
(AXIO, Carl Zeiss Corporation, Germany).
Flow cytometric analysis
After treatment with nocodazole, cells were harvested by
trypsinization and washed once with PBS (pH 7.4). Cells were
resuspended in 1 mL of 0.9% NaCl, and 2.5 mL of ice-cold 90%
ethanol were added. After incubation at room temperature for
30 min, cells were centrifuged and the supernatant was removed.
Cells were resuspended in 1 mL PBS containing 50 mg/mL
propidium iodide (PI) and 100 mg/mL ribonuclease A and
incubated at 37uC for 30 min. After centrifugation, cells were
resuspended in PBS. Flow cytometric analysis was performed on a
flow cytometer (model BD LSR II, BD Bioscience, San Jose, CA).
Small interfering RNA (siRNA) treatment
The role of cyclin B1, Cdc2, and MAD2 in mediating
nocodazole-induced cell cycle arrest was examined using siRNAs
to selectively silence cyclin B1, Cdc2, and MAD2 genes. The
cyclin B1 siRNAs (si-cyclin B1, catalog no. sc-29284, Santa Cruz),
Cdc2 siRNAs (si-Cdc2, catalog no. sc-29252, Santa Cruz), MAD2
Nocodazole-Induced Prometaphase Arrest
PLoS ONE | www.plosone.org 11 August 2011 | Volume 6 | Issue 8 | e24312siRNAs (si-MAD2, catalog no. sc-35837, Santa Cruz), and the
siRNA negative control (si-Con, catalog no. sc-37007, Santa Cruz)
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
According to the supplier, each of the above siRNA preparations
contains a combination of three target-specific RNA sequences
that were designed to selectively knock down the expression of the
corresponding target gene. MCF-7 cells were seeded the night
before transfection, reaching a density of 30–50% confluence by
the time of transfection. Forty nmol of si-cyclin B1, si-Cdcd2, si-
MAD2, and si-Con were used for transfection using Lipofectamine
2000 (Invitrogen, San Diego, CA, USA) according to the
instructions of the manufacturers. Transfected cells were main-
tained in culture for 2 days before harvesting and/or further
analyses. The efficiency of the siRNA knockdown was determined
by Western blot analysis.
Statistical analysis
At least three separate experiments were performed for each
measurement. All quantitative data were expressed as mean 6
S.D. Comparisons between two groups were analyzed using two-
way ANOVA. Individual differences among groups were analyzed
using the Dunnett’s test (SPSS-11.5 software). P,0.05 or P,0.01
was considered statistically significant or statistically very signifi-
cant, respectively.
Supporting Information
Figure S1 Induction of cell cycle arrest and cyclin B1/
Cdc2 up-regulation in MDA-MB-435s cells by nocodazole
(Noco). A. Time-dependent induction of mitotic arrest following
treatment with nocodazole. MDA-MB-435s cells were seeded in 6-
well plates at 5610
4 cells/mL and then treated with 250 nM
nocodazole for 12 and 24 h. Cells were harvested and analyzed
using flow cytometry (left panel). Cells were also stained with
Hoechst-33258, and examined under a fluorescence microscopy
(right panel) (at 1006magnification). As shown, many MDA-MB-
435s cells are arrested in mitosis (prometaphase) after treatment
with 250 nM nocodazole. B. Quantitation of the percentage of
cells arrested in prometaphase (based on counting 200 or more
nuclei in each sample) under a fluorescence microscope. Each bar
is the mean 6 S.D. from three measurements. * P,0.05 versus
vehicle-treated controls. C. Time-dependent change in cyclin B1
and Cdc2 protein levels following nocodazole treatment. MDA-
MB-435s cells were treated with nocodazole (250 nM) for 12 h,
and total lysates were prepared. Western blots were detected using
specific antibodies against cyclin B1 and Cdc2. Membrane was
stripped for determining the levels of GAPDH as a loading
control.
(TIF)
Figure S2 Induction of cell cycle arrest and cyclin B1/
Cdc2 activation in MCF-10A cells by nocodazole (Noco).
A. Both MCF-7 and MCF-10A cells were cultured in 96-well
plates at 5,000 cells/well. Cells were incubated for 24 h allow for
attachment. A time-dependent study was conducted with the
intervals of 2, 3, and 4 days, respectively. The relative cell density
was detected by crystal violet staining. B. MCF-10A cells were
seeded in 6-well plates at 5610
4 cells/mL and then treated with
125 nM nocodazole for 12 and 24 h. Cells were stained with
Hoechst-33258, and examined under fluorescence microscopy (at
2006 magnification). C. Quantitation of the percentage of cells
arrested in prometaphase (based on counting 200 or more nuclei
in each sample) under a fluorescence microscope. Each bar is the
mean 6 S.D. value from three determinations. * P,0.05 versus
vehicle-treated control. D. Cyclin B1 and Cdc2 protein levels
following nocodazole treatment. MCF-10A cells were treated with
nocodazole (125 nM) for the period as indicated, and total lysates
were prepared. Western blots were detected using specific
antibodies against cyclin B1 and Cdc2. Membrane was stripped
for determining the levels of GAPDH as a loading control.
(TIF)
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